APA

Smretschnig E., Hagen S., Glittenberg C., Ristl R., Krebs I., Binder S. & Ansari-Shahrezaei S. (20170321). Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. : Eye (London, England).

Chicago

Smretschnig E, Hagen S, Glittenberg C, Ristl R, Krebs I, Binder S and Ansari-Shahrezaei S. 20170321. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. : Eye (London, England).

Harvard

Smretschnig E., Hagen S., Glittenberg C., Ristl R., Krebs I., Binder S. and Ansari-Shahrezaei S. (20170321). Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. : Eye (London, England).

MLA

Smretschnig E, Hagen S, Glittenberg C, Ristl R, Krebs I, Binder S and Ansari-Shahrezaei S. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. : Eye (London, England). 20170321.